α1-3/4 fucosylation at Asn 241 of β-haptoglobin is a novel marker for colon cancer: A combinatorial approach for development of glycan biomarkers

International Journal of Cancer

Volumn 130, Issue 10, 2012, Pages 2366-2376

  Park, Seung Yeol ^a   Lee, Sung Hyeon ^a   Kawasaki, Nana ^b   Itoh, Satsuki ^b   Kang, Keunsoo ^a   Hee Ryu, Soo ^a   Hashii, Noritaka ^b   Kim, Jin Man ^c   Kim, Ji Yeon ^c   Hoe Kim, Jung ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^c Chungnam National University   (South Korea)

Author keywords

colon cancer; haptoglobin; lectin blotting; mass spectrometry; microarray

Indexed keywords

ALEURIA AURANTIA LECTIN; ALPHA LEVO FUCOSIDASE; ASPARAGINE; BETA HAPTOGLOBIN; EPITOPE; HAPTOGLOBIN; PLANT LECTIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASCENDING COLON; CANCER GROWTH; CANCER STAGING; CANCER TISSUE; CARBOHYDRATE ANALYSIS; CECUM; CELL MEMBRANE; COLON CANCER; CONTROLLED STUDY; CROHN DISEASE; DESCENDING COLON; ENTERITIS; FEMALE; FUCOSYLATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGMOID; TECTUM; TRANSVERSE COLON; TUMOR CELL; ULCERATIVE COLITIS; WESTERN BLOTTING;

AGED; ASPARAGINE; COLON; COLONIC NEOPLASMS; FEMALE; FUCOSE; GLYCOSYLATION; HAPTOGLOBINS; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; POLYSACCHARIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84857881654     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26288     Document Type: Article

References (28)

1. Hakomori S,. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci USA 2002; 99: 10231-3.
2. Turner GA,. N-glycosylation of serum proteins in disease and its investigation using lectins. Clin Chim Acta 1992; 208: 149-71.
3. Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, Taketa K, Endo Y, Nagataki S,. Early recognition of hepatocellular carcinoma based on altered profiles of α-fetoprotein. N Engl J Med 1993; 328: 1802-6. (Pubitemid 23174710)
4. Shiraki K, Takase K, Tameda Y, Hamada M, Kosaka Y, Nakano T,. A clinical-study of lectin-reactive α-fetoprotein as an early indicator of hepatocellular-carcinoma in the follow-up of cirrhotic-patients. Hepatology 1995; 22: 802-7.
5. Fukushima K, Satoh T, Baba S, Yamashita K,. α1,2-Fucosylated and β-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer. Glycobiology 2010; 20: 452-60.
6. Saldova R, Fan Y, Fitzpatrick JM, Watson RWG, Rudd PM,. Core fucosylation and α2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology 2010; 21: 195-205.
7. Saldova R, Royle L, Radcliffe CM, Abd Hamid UM, Evans R, Arnold JN, Banks RE, Hutson R, Harvey DJ, Antrobus R, Petrescu SM, Dwek RA, et al. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 2007; 17: 1344-56. (Pubitemid 350131311)
8. Harazono A, Kawasaki N, Itoh S, Hashii N, Matsuishi-Nakajima Y, Kawanishi T, Yamaguchi T,. Simultaneous glycosylation analysis of human serum glycoproteins by high-performance liquid chromatography/tandem mass spectrometry. J Chromatogr B 2008; 869: 20-30.
9. Turner GA,. Haptoglobin. A potential reporter molecule for glycosylation changes in disease. Adv Exp Med Biol 1995; 376: 231-8.
10. Langlois MR, Delanghe JR,. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996; 42: 1589-600. (Pubitemid 26354735)
11. Nakano M, Nakagawa T, Ito T, Kitada T, Hijioka T, Kasahara A, Tajiri M, Wada Y, Taniguchi N, Miyoshi E,. Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers. Int J Cancer 2008; 122: 2301-9. (Pubitemid 351542335)
12. Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, Tennant BC, London WT, Evans AA, Blumberg BS, Dwek RA, Mattu TS, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci USA 2005; 102: 779-84. (Pubitemid 40282742)
13. Marino K, Bones J, Kattla JJ, Rudd PM,. A systematic approach to protein glycosylation analysis: a path through the maze. Nat Chem Biol 2010; 6: 713-23.
14. Hsu K-L, Pilobello KT, Mahal LK,. Analyzing the dynamic bacterial glycome with a lectin microarray approach. Nat Chem Biol 2006; 2: 153-7. (Pubitemid 44323867)
15. Fujimura T, Shinohara Y, Tissot B, Pang PC, Kurogochi M, Saito S, Arai Y, Sadilek M, Murayama K, Dell A, Nishimura S, Hakomori SI,. Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects. Int J Cancer 2008; 122: 39-49. (Pubitemid 350209976)
16. Okuyama N, Ide Y, Nakano M, Nakagawa T, Yamanaka K, Moriwaki K, Murata K, Ohigashi H, Yokoyama S, Eguchi H, Ishikawa O, Ito T, et al. Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer 2006; 118: 2803-8. (Pubitemid 43673360)
17. Kukowska-Latallo JF, Larsen RD, Nair RP, Lowe JB,. A cloned human cDNA determines expression of a mouse stage-specific embryonic antigen and the Lewis blood group α(1,3/1,4)fucosyltransferase. Genes Dev 1990; 4: 1288-303.
18. Hanski C, Klußmann E, Wang J, Böhm C, Ogorek D, Hanski ML, Krüger-Krasagakes S, Eberle J, Schmitt-Gräff A, Riecken EO,. Fucosyltransferase III and sialyl-Le(x) expression correlate in cultured colon carcinoma cells but not in colon carcinoma tissue. Glycoconj J 1996; 13: 727-33. (Pubitemid 26354265)
19. Majuri ML, Niemelä R, Tiisala S, Renkonen O, Renkonen R,. Expression and function of α2,3-sialyl- and α,3/l,4-fucosyltransferases in colon adenocarcinoma cell lines: role in synthesis of E-selectin counter-receptors. Int J Cancer 1995; 63: 551-9.
20. Park S-Y, Yoon S-J, Jeong Y-T, Kim J-M, Kim J-Y, Bernert B, Ullman T, Itzkowitz SH, Kim J-, Hakomori S-I,. N-glycosylation status of β-haptoglobin in sera of patients with colon cancer, chronic inflammatory diseases and normal subjects. Int J Cancer 2010; 126: 142-55.
21. Goodarzi MT, Turner GA,. Decreased branching, increased fucosylation and changed sialylation of α-1-proteinase inhibitor in breast and ovarian cancer. Clin Chim Acta 1995; 236: 161-71.
22. Itzkowitz SH,. Blood group-related carbohydrate antigen expression in malignant and premalignant colonic neoplasms. J Cell Biochem 1992; 50: 97-101.
23. Aoyagi Y, Isemura M, Suzuki Y, Sekine C, Soga K, Ozaki T, Ichida F,. Change in fucosylation of α-fetoprotein on malignant transformation of liver cells. Lancet 1986; 327: 210. (Pubitemid 16135538)
24. Hakomori S, Nudelman ED, Levery SB, Kannagi R,. Novel fucolipids accumulating in human adenocarcinoma. I. Glycolipids with di- or trifucosylated type 2 chain. J Biol Chem 1984; 259: 4672-80. (Pubitemid 14131378)
25. Miyoshi E, Nakano M,. Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures. Proteomics 2008; 8: 3257-62.
26. Thompson S, Turner GA,. Elevated levels of abnormally-fucosylated haptoglobins in cancer sera. Br J Cancer 1987; 56: 605-10. (Pubitemid 17165655)
27. Lee S, Bang S, Song K, Lee I,. Differential expression in normal-adenoma-carcinoma sequence suggests complex molecular carcinogenesis in colon. Oncol Rep 2006; 16: 747-54.
28. Narisada M, Kawamoto S, Kuwamoto K, Moriwaki K, Nakagawa T, Matsumoto H, Asahi M, Koyama N, Miyoshi E,. Identification of an inducible factor secreted by pancreatic cancer cell lines that stimulates the production of fucosylated haptoglobin in hepatoma cells. Biochem Biophys Res Commun 2008; 377: 792-6.